



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/978,273	10/15/2001	Christopher John Robert Thomas	9341-027-999	4447

20583 7590 03/11/2003

PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 100362711

EXAMINER

COLLINS, CYNTHIA E

ART UNIT

PAPER NUMBER

1638

DATE MAILED: 03/11/2003

8

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Applicant N N .

09/978,273

Examiner

Cynthia Collins

Applicant(s)

THOMAS ET AL.

Art Unit

1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-27 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-27 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: ____.

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-2, 6, 10-17 and 21-22, drawn to a method of producing a transformed plant by transforming a plant with a chimaeric gene comprising a promoter operably linked to a coding sequence as set forth in SEQ ID NO:1 encoding a maize ribosome inactivating protein comprising a pro-maize ribosome inactivating protein comprising the N-terminal, the α domain, the central spacer peptide, the β domain and the C-terminal peptide, classified in class 800, subclass 278, for example.
- II. Claims 1, 3, 7, 10-17 and 21-22, drawn to a method of producing a transformed plant by transforming a plant with a chimaeric gene comprising a promoter operably linked to a coding sequence as set forth in SEQ ID NO:2 encoding a maize ribosome inactivating protein comprising a recombinant mature RIP comprising an α domain and a β domain arranged contiguously, classified in class 800, subclass 290, for example.
- III. Claims 1, 4, 8, 10-17 and 21-22, drawn to a method of producing a transformed plant by transforming a plant with a chimaeric gene comprising a promoter operably linked to a coding sequence as set forth in SEQ ID NO:3 encoding a maize ribosome inactivating protein comprising a recombinant RIP comprising as the active part the α domain only, classified in class 435, subclass 468, for example.

- IV. Claims 1, 5, 9-17 and 21-22, drawn to a method of producing a transformed plant, cell and plant by transforming a plant with a chimaeric gene comprising a promoter operably linked to a coding sequence as set forth in SEQ ID NO:4 encoding a maize ribosome inactivating protein comprising a recombinant RIP comprising as the active part the β domain only, classified in class 435, subclass 419, for example.
- V. Claims 18-22, drawn to a method of producing a transformed plant by transforming a plant with a chimaeric gene comprising a first promoter operably linked to an α domain of a maize ribosome inhibiting protein and a second promoter operably linked to a β domain of a maize ribosome inhibiting protein, classified in class 800, subclass 287, for example.
- VI. Claims 23 and 26, drawn to a DNA isolate of a chimaeric gene comprising a promoter operably linked to a coding sequence encoding a maize ribosome inactivating protein or a part thereof, classified in class 536, subclass 23.6, for example.
- VII. Claims 24-25 and 27, drawn to a DNA isolate of a chimaeric gene comprising a first promoter operably linked to a first domain of a maize ribosome inactivating protein and a second promoter operably linked to a second domain of a maize ribosome inactivating protein, classified in class 435, subclass 320.1, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation. Each of the five methods requires the use of a different and structurally distinct chimaeric gene.

Inventions VI and VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation. The two chimaeric genes are different and structurally distinct from each other.

Inventions VI and I-IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the DNA isolate of a chimaeric gene can be used in a materially different process of using that product, such as a hybridization method or a method of producing a recombinant polypeptide.

Inventions VII and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the DNA isolate of a chimaeric gene can be used in a materially

Art Unit: 1638

different process of using that product, such as a hybridization method or a method of producing a recombinant polypeptide.

Applicants are reminded that nucleotide sequences encoding different amino acid sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute **independent and distinct** inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq. This requirement is not to be construed as a requirement for an election of species, since each nucleotide and amino acid sequence is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, their recognized divergent subject matter, and the requirement for different areas of search, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Application/Control Number: 09/978,273
Art Unit: 1638

Page 6

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Remarks

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cynthia Collins whose telephone number is (703) 605-1210. The examiner can normally be reached on Monday-Friday 8:45 AM -5:15 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (703) 306-3218. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

CC
March 6, 2003

DAVID T. FOX
PRIMARY EXAMINER
GROUP 180/1638

